Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G

Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.

Ohad Cohen likened Medtronic's 780G to a Ferrari compared to other treatments, which he described as a donkey. • Source: Shutterstock

Medtronic has continued to publish more good news about the device it is banking on to save its fortunes in the diabetes management devices market.

What Is The 780G?

When combined with a compatible glucose monitor, Medtronic’s 780G pump creates a hybrid closed-loop system – the closest approximation of an “artificial pancreas” currently available to people with diabetes.

The glucose monitor measures blood glucose levels and the pump delivers insulin in response to current readings. Additionally, predictive algorithms estimate future blood glucose levels, ensuring more regular glycemic control.

For patients, this creates a much more hands-off experience, where manual involvement is typically only needed before a carb or sugar heavy meal

Medtronic has been struggling to compete with Abbott and DexCom over the past three years because it does not have a competitive glucose control system, but it expects the 780G insulin pump with the Guardian 4 continuous glucose monitor, supported by compelling data from the

More from Clinical Trials

More from R&D